WO2017034242A3 - 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물 - Google Patents

신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물 Download PDF

Info

Publication number
WO2017034242A3
WO2017034242A3 PCT/KR2016/009196 KR2016009196W WO2017034242A3 WO 2017034242 A3 WO2017034242 A3 WO 2017034242A3 KR 2016009196 W KR2016009196 W KR 2016009196W WO 2017034242 A3 WO2017034242 A3 WO 2017034242A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
pharmaceutical composition
catechol derivative
novel catechol
novel
Prior art date
Application number
PCT/KR2016/009196
Other languages
English (en)
French (fr)
Other versions
WO2017034242A2 (ko
Inventor
김환묵
정광원
오승현
김선기
김정주
송성원
Original Assignee
주식회사 오토파지사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US15/751,707 priority Critical patent/US10662169B2/en
Priority to CA2994377A priority patent/CA2994377C/en
Priority to MX2018002177A priority patent/MX2018002177A/es
Priority to ES16839531T priority patent/ES2865335T3/es
Priority to JP2018508206A priority patent/JP6811234B2/ja
Priority to CN201680046879.0A priority patent/CN107922374B/zh
Priority to AU2016312736A priority patent/AU2016312736A1/en
Priority to BR112018003313-8A priority patent/BR112018003313A2/pt
Application filed by 주식회사 오토파지사이언스 filed Critical 주식회사 오토파지사이언스
Priority to EP16839531.7A priority patent/EP3339299B1/en
Publication of WO2017034242A2 publication Critical patent/WO2017034242A2/ko
Publication of WO2017034242A3 publication Critical patent/WO2017034242A3/ko
Priority to IL257621A priority patent/IL257621B/en
Priority to US16/833,280 priority patent/US20200255397A1/en
Priority to AU2021202309A priority patent/AU2021202309B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
    • C07D333/10—Thiophene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

본 발명은 화학식 1로 표시되는 화합물, 또는 이의 약학적으로 허용가능한 염에 관한 것으로, 본 발명에 따른 화합물은 아토파지 (autophagy) 관련 질환의 예방 또는 치료에 유용하게 사용할 수 있다.
PCT/KR2016/009196 2015-08-21 2016-08-19 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물 WO2017034242A2 (ko)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU2016312736A AU2016312736A1 (en) 2015-08-21 2016-08-19 Novel catechol derivative and pharmaceutical composition comprising same
MX2018002177A MX2018002177A (es) 2015-08-21 2016-08-19 Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
ES16839531T ES2865335T3 (es) 2015-08-21 2016-08-19 Nuevo derivado de catecol y composición farmacéutica que lo comprende
JP2018508206A JP6811234B2 (ja) 2015-08-21 2016-08-19 新規なカテコール誘導体およびこれを含む薬学的組成物
CN201680046879.0A CN107922374B (zh) 2015-08-21 2016-08-19 新型儿茶酚衍生物及含有它的药物组合物
US15/751,707 US10662169B2 (en) 2015-08-21 2016-08-19 Catechol derivative and pharmaceutical composition comprising the same
BR112018003313-8A BR112018003313A2 (pt) 2015-08-21 2016-08-19 novo derivado de catecol e composição farmacêutica compreendendo o mesmo
CA2994377A CA2994377C (en) 2015-08-21 2016-08-19 Novel catechol derivative and pharmaceutical composition comprising the same
EP16839531.7A EP3339299B1 (en) 2015-08-21 2016-08-19 Novel catechol derivative and pharmaceutical composition comprising same
IL257621A IL257621B (en) 2015-08-21 2018-02-19 A catechol derivative and a pharmaceutical preparation that includes it
US16/833,280 US20200255397A1 (en) 2015-08-21 2020-03-27 Method for treating liver disease by administering pharmaceutical composition comprising catechol derivative
AU2021202309A AU2021202309B2 (en) 2015-08-21 2021-04-16 Novel catechol derivatives and pharmaceutical composition comprising the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0118247 2015-08-21
KR1020150118247A KR102100470B1 (ko) 2015-08-21 2015-08-21 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/751,707 A-371-Of-International US10662169B2 (en) 2015-08-21 2016-08-19 Catechol derivative and pharmaceutical composition comprising the same
US16/833,280 Division US20200255397A1 (en) 2015-08-21 2020-03-27 Method for treating liver disease by administering pharmaceutical composition comprising catechol derivative

Publications (2)

Publication Number Publication Date
WO2017034242A2 WO2017034242A2 (ko) 2017-03-02
WO2017034242A3 true WO2017034242A3 (ko) 2017-04-20

Family

ID=58100312

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/009196 WO2017034242A2 (ko) 2015-08-21 2016-08-19 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물

Country Status (13)

Country Link
US (2) US10662169B2 (ko)
EP (1) EP3339299B1 (ko)
JP (1) JP6811234B2 (ko)
KR (1) KR102100470B1 (ko)
CN (1) CN107922374B (ko)
AU (2) AU2016312736A1 (ko)
BR (1) BR112018003313A2 (ko)
CA (1) CA2994377C (ko)
CL (1) CL2018000420A1 (ko)
ES (1) ES2865335T3 (ko)
IL (1) IL257621B (ko)
MX (1) MX2018002177A (ko)
WO (1) WO2017034242A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020022220A2 (pt) 2018-06-01 2021-02-02 Autophagysciences Inc. novo composto e composição farmacêutica compreendendo o mesmo
AU2019304832A1 (en) * 2018-07-20 2021-01-21 Hexapharmatec Co., Ltd. Novel catechol derivatives or salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
KR20210130016A (ko) 2020-04-21 2021-10-29 (주)헥사파마텍 신규의 2-아릴티아졸 유도체 또는 이의 염, 이의 제조방법, 및 이를 함유하는 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030206A1 (en) * 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
WO2005079791A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
WO2007035478A2 (en) * 2005-09-20 2007-03-29 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1355555A (en) * 1919-10-22 1920-10-12 Howk John Simeon Spring-controller
DE3864248D1 (de) * 1987-12-14 1991-09-19 Sawai Seiyaku Kk Carboxamide mit tetrazol- und thiazol-ringen und ihre anwendung.
US9321730B2 (en) 2007-08-21 2016-04-26 The Hong Kong Polytechnic University Method of making and administering quinoline derivatives as anti-cancer agents
KR101692047B1 (ko) * 2010-11-30 2017-01-04 연세대학교 산학협력단 오토파지 관련 질환, 혈관신생질환 또는 멜라닌 관련 질환의 예방 또는 치료용 약제학적 조성물
WO2012083866A1 (en) 2010-12-22 2012-06-28 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030206A1 (en) * 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
WO2005079791A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
WO2007035478A2 (en) * 2005-09-20 2007-03-29 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE Chemical Abstract 2 March 2007 (2007-03-02), retrieved from STN Database accession no. 92439941-7 *
DATABASE Chemical Abstract 6 August 2012 (2012-08-06), XP055515638, retrieved from STN Database accession no. 1386641-70-8 *
DATABASE Chemical Abstract 7 August 2012 (2012-08-07), XP055515657, retrieved from STN Database accession no. 1387633-13-7 *
DATABASE Chemical Abstract 7 February 2012 (2012-02-07), XP055515662, retrieved from STN Database accession no. 1355555-80-4 *
DATABASE STN [O] 15 February 2007 (2007-02-15), XP055515635, retrieved from STN Database accession no. 921180-99-6 *
SCHOFFMANN, A. ET AL.: "Efficient Modulation of gamma-aminobutyric Acid Type A Receptors by Piperine Derivatives", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 13, 2014, pages 5602 - 5619, XP055375728 *

Also Published As

Publication number Publication date
AU2021202309B2 (en) 2022-06-23
JP2018529653A (ja) 2018-10-11
US20180244644A1 (en) 2018-08-30
CN107922374A (zh) 2018-04-17
EP3339299A2 (en) 2018-06-27
JP6811234B2 (ja) 2021-01-13
US10662169B2 (en) 2020-05-26
KR102100470B1 (ko) 2020-04-13
CA2994377C (en) 2023-10-10
CA2994377A1 (en) 2017-03-02
MX2018002177A (es) 2018-06-06
ES2865335T3 (es) 2021-10-15
EP3339299B1 (en) 2021-03-03
KR20170022790A (ko) 2017-03-02
AU2021202309A1 (en) 2021-05-13
AU2021202309A2 (en) 2021-07-22
AU2016312736A1 (en) 2018-03-08
EP3339299A4 (en) 2019-01-16
CL2018000420A1 (es) 2018-08-10
BR112018003313A2 (pt) 2018-09-18
WO2017034242A2 (ko) 2017-03-02
IL257621A (en) 2018-04-30
US20200255397A1 (en) 2020-08-13
IL257621B (en) 2021-02-28
CN107922374B (zh) 2020-11-06

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12016502595B1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
EP4316591A3 (en) Oxysterols and methods of use thereof
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
WO2016112875A3 (zh) 二联苯衍生物及其应用
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2017034242A3 (ko) 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물
PH12016502568B1 (en) Novel heterocyclic compound
WO2015001541A3 (en) Pharmaceutical film composition
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
SG11201803867TA (en) Sodium channel blocker
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
WO2015181837A3 (en) Novel compounds as anti-tubercular agents
WO2018080215A8 (en) 3-AMINO ALKYLATED INDOLE DERIVATIVE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF
WO2015154883A8 (en) Neosoraphens
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16839531

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2994377

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018508206

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15751707

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 257621

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/002177

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2016312736

Country of ref document: AU

Date of ref document: 20160819

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2016839531

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018003313

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112018003313

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180220